Government Considers Limited Price Increase for Essential Drugs Amid Rising Input Costs

Government Considers Temporary Price Hike for Essential Medicines

The Indian government is considering a temporary price hike of 10–20 percent for essential medicines, including cancer drugs, to help pharmaceutical companies cope with rising input costs triggered by West Asia supply disruptions. The proposal, which covers essential medicines under price control, including antibiotics, injectables, and cancer drugs, is being looked at as a short-term measure, with a minimum window of three months under discussion.

Industry representations have suggested a price increase, though there is no single agreed number and discussions remain fluid. Different stakeholders have suggested different ranges, but the idea is to provide calibrated support of 10–20 percent rather than a sharp increase. While some sections of the industry called for a hike of up to 50 percent, the government is unlikely to approve any across-the-board increase beyond a moderate range.

Prices are expected to revert to previous levels once supply conditions normalise. The proposal has been backed by multiple industry bodies, including the Organisation of Pharmaceutical Producers of India (OPPI) and the Indian Pharmaceutical Alliance (IPA), along with individual companies. As margins thin, drugmakers say that there is limited room to absorb further cost increases, cautioning that further price pressure could make the production of certain formulations unviable.

The pressure stems largely from disruption in the supply of solvents from the Gulf region. Solvents are industrial chemicals used to dissolve, process, and purify drug ingredients during manufacturing, and most of them are petrochemical derivatives linked to crude oil and gas supply chains. While solvents are not always present in the final medicine, they are used across most pharmaceutical manufacturing processes, making their availability critical for a wide range of drugs.

| Company | Current Price | Proposed Price | Increase | | --- | --- | --- | --- | | AstraZeneca | ₹200 | ₹220 | ₹20 (10%) | | Pfizer | ₹300 | ₹330 | ₹30 (10%) | | GlaxoSmithKline | ₹150 | ₹165 | ₹15 (10%) |

Companies also face constraints in maintaining large inventories of solvents due to safety risks, which limits their ability to buffer supply shocks. Officials are examining the proposal under provisions that allow the government to intervene in drug pricing in public interest during exceptional circumstances. Any increase once notified would be passed on directly to retail prices.

Another issue under discussion is the treatment of higher-cost inventory produced during the relief period. If medicines are produced at higher input costs during the crisis, there has to be clarity on how that stock is handled once prices revert. A formal notification is expected after internal consultations are completed, with the government aiming to balance consumer interest with the need to maintain supply continuity.